GSK2245035

Phase 2Small molecule

GSK

GSK2245035 is one of 102 small molecule programs targeting Allergic Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic AsthmaActive, not recruiting

Systemic SclerosisActive, not recruiting

AsthmaActive, not recruiting

Allergic AsthmaPhase 2

Active, not recruiting

Systemic SclerosisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Xolair

Roche

Preclinical

25 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Cinqair

Teva

Preclinical

13 6

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 7

Asmanex

Novartis

Preclinical

5 8

Celexa

AbbVie

Preclinical

1 9

Spiriva

Boehringer Ingelheim

Preclinical

8 10

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergies1 trial

To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies

Completed· GSK logo

GSK·Phase 2·NCT01788813·42 enrolled

Allergic Asthma1 trial

A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma

Withdrawn· GSK logo

GSK·Phase 2·NCT03707678

Intranasal Administration1 trial

A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies

Completed· GSK logo

GSK·Phase 2·NCT01607372·18 enrolled

Asthma1 trial

Effect of the GSK2245035 on the Allergen-induced Asthmatic Response

Completed· GSK logo

GSK·Phase 2·NCT02833974·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for GSK2245035. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK2245035 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK2245035. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

GSK2245035

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergies1 trial

Allergic Asthma1 trial

Intranasal Administration1 trial

Asthma1 trial

References

Drug Info

Quick Facts

Related News